Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Эффективность и переносимость препарата Тарка у больных артериальной гипертензией (программа ТАНДЕМ) - Журнал Системные Гипертензии №2 (2008)
Эффективность и переносимость препарата Тарка у больных артериальной гипертензией (программа ТАНДЕМ)
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. М.: Медиа Медика, 2007.
2. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56 (1): 43–52.
3. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I2.
4. Miura K, Daviglus ML, Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501–8.
5. Lewington S, Clarke R, Qizilbash N et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
6. Coldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorthiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibirors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5.
7. Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579–603.
8. Elliott HL, Meredith PA. Clinical implications of the trough-peak ratio. Blood pressure Monit 1996; 6 (suppl. 1): 47–51.
9. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl 1997; 15 (2): 51–3.
10. Staessen JA, Bieniaszewski L, O'Brien ET et al. An epidemiological approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Pres Monitor 1996; 1: 13–26.
11. Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, cross-over study. Am J Cardiol 1985; 55: 680–7.
12. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153 (5): 598–615.
13. Fernandez R., Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849–56.
14. Bakris G, Molitch M, Hewkin A et al. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592–7.
2. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest 1969; 56 (1): 43–52.
3. Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I2.
4. Miura K, Daviglus ML, Dyer AR et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001; 161 (12): 1501–8.
5. Lewington S, Clarke R, Qizilbash N et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 (9349): 1903–13.
6. Coldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorthiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibirors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–5.
7. Tatti P, Pahor M, Buington R et al. Outcome results of the Fosinipril versus Amlodipine Cardiovascular events randomized trial (FACET) in patients with hypertension and NDDM. Diabetes Care 1998; 21: 579–603.
8. Elliott HL, Meredith PA. Clinical implications of the trough-peak ratio. Blood pressure Monit 1996; 6 (suppl. 1): 47–51.
9. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens Suppl 1997; 15 (2): 51–3.
10. Staessen JA, Bieniaszewski L, O'Brien ET et al. An epidemiological approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Pres Monitor 1996; 1: 13–26.
11. Johnston D, Lesoway R, Humen D, Kostuk W. Clinical and hemodynamic evaluation of propranolol in combination with verapamil, nifedipine and diltiazem in exertional angina pectoris: a placebo-controlled, double-blind, randomized, cross-over study. Am J Cardiol 1985; 55: 680–7.
12. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153 (5): 598–615.
13. Fernandez R., Puig JG, Rodriguez-Perez JC et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849–56.
14. Bakris G, Molitch M, Hewkin A et al. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592–7.
Авторы
И.Е.Чазова, Л.Г.Ратова
ФГУ РКНПК Росмедтехнологий, Москва
ФГУ РКНПК Росмедтехнологий, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.